Related Experiment Videos
Immunophenotypic subclassification of chronic lymphocytic leukaemia (CLL)
A S Kurec1, G A Threatte, A J Gottlieb
1Department of Pathology, SUNY Health Science Center, Syracuse 13210.
British Journal of Haematology
|May 1, 1992
Summary
Immunophenotypic heterogeneity in B-cell chronic lymphocytic leukemia (CLL) defines at least four subgroups. While myeloid or T-cell antigen expression doesn't predict survival, CD5 negativity is linked to advanced disease and poorer outcomes in CLL patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- B-cell chronic lymphocytic leukemia (CLL) exhibits immunophenotypic heterogeneity.
- Understanding this heterogeneity is crucial for accurate prognostication and patient management.
Purpose of the Study:
- To investigate the significance of immunophenotypic variations in newly diagnosed B-cell CLL.
- To identify distinct subgroups based on surface markers and correlate them with clinical features and survival.
Main Methods:
- Peripheral blood samples from 61 newly diagnosed CLL cases were analyzed.
- Immunophenotyping was performed using surface immunoglobulins (SIgs), mouse rosette assays (MR), and monoclonal antibodies for B, T, and myeloid cells.
- Cases were categorized into four groups based on immunophenotypic profiles.
Main Results:
- Four distinct immunophenotypic subgroups of B-cell CLL were identified.
- The CD5-negative subgroup (Group III) showed significantly lower hemoglobin, higher Rai stage, and poorer 5-year survival.
- Expression of myeloid or T-cell antigens did not predict patient survival.
Conclusions:
- At least four distinct immunophenotypic subgroups of B-cell CLL exist.
- Lack of CD5 antigen expression is associated with advanced disease stage and poorer patient survival in CLL.
- Myeloid or T-cell antigen expression is not a significant prognostic factor for survival in CLL.